Skip to main content

Table 2 Projected impact of the validated EPI 15.6 and adjusted cut-points 20 and 29.6 (with presumed 100% compliance) on expected biopsies performed and avoided

From: A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy

EPI cut point

Expected Biopsies Performed

Expected Biopsies Avoided

Delayed GG2

Delayed ≥GG3

NPV

Sensitivity

Specificity

15.6

170 (74%)

59 (26%)

2

3

91.5 (81.3–97.2)

82.1 (63.1–93.9)

26.9 (20.9–33.6)

20

149 (65%)

80 (35%)

2

3

93.8 (86.0–97.9)

82.1 (63.1–93.9)

37.3 (30.6–44.4)

29.6

89 (39%)

140 (61%)

2

6

93.6 (88.1–97.0)

67.9 (47.6–84.1)

65.2 (58.2–71.7)